Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2463${count})

  • Rapid Response Innovation Awards, 2009
    Serum Biomarkers for Parkinson's Disease

    Objective/Rationale
    The immune system appears to play an important role in the progression of Parkinson’s disease, and immunotherapy may offer an approach to slow or stop disease progression. The...

  • Rapid Response Innovation Awards, 2009
    Small Molecule Inhibitors of Alpha-synuclein Assembly and Toxicity

    Objective/Rationale:
    We will test a novel drug candidate that blocks formation of the toxic aggregates of the protein alpha-synuclein, which are believed to cause Parkinson’s disease (PD). Our drug...

  • Rapid Response Innovation Awards, 2009
    Glycine Uptake Inhibitors as Potential Enhancers of Dopaminergic Axon Regeneration

    Objective/Rationale
    An important goal in Parkinson’s disease therapy is to restore the loss of the dopaminergic innervation of the striatum. Cell culture data from our lab indicate that activation of...

  • Rapid Response Innovation Awards, 2009
    Multi-site Coordinated Reset Stimulation of the Subthalamic Nucleus

    Objective/Rationale:
    Current deep brain stimulation (DBS) does not take advantage of the latest discoveries of Parkinson’s disease (PD) pathophysiology which may explain some of its limitations...

  • Rapid Response Innovation Awards, 2009
    The Role of Casein Kinase 2 in the Modulation of Dopamine Signaling in Parkinson's Disease

    Objective/Rationale:
    Parkinson’s disease is caused by a selective loss of cells in the brain that produce the neurotransmitter dopamine. The major treatment for PD is Levodopa (L-Dopa) which gets...

  • Target Validation, 2009
    The Transcription Factor Nrf2 as a Target to Reduce Neurodegeneration and Neuroinflammation in Parkinson's Disease

    Objective/Rationale:
    Dopaminergic neuron loss and exacerbated neuroinflammation are events tightly involved in PD pathology that may result from an inadequate response to toxic, oxidant or inflammatory...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.